Blue Cross Blue Shield - Iowa Prior Authorization Lookup
Latest Blue Cross Blue Shield - Iowa prior authorization updates25
- Prior AuthClinical/Medical PolicyEff. 2026-12-09Sohonos (palovarotene) coverage for fibrodysplasia ossificans progressivaThis policy governs prior authorization and coverage of Sohonos (palovarotene) for reducing new heterotopic ossification in members with fibrodysplasia ossificans progressiva (FOP). Coverage applies when the specified diagnosis, age, safety, reproductive-status, specialist, and response-to-therapy requirements are met.All Blue Cross Blue Shield - Iowa updates
- Prior AuthClinical/Medical PolicyEff. 2026-10-27High Dollar Drug ReviewReview of high-dollar pharmacy and medical drug claims for clinical appropriateness, dosing, quantity, duration, coding, billed units, and cost when drugs are not already managed under drug-specific prior authorization criteria.All Blue Cross Blue Shield - Iowa updates
- Prior AuthClinical/Medical PolicyEff. 2026-10-25Pasatru (garetosmab-grts) Coverage for Fibrodysplasia Ossificans ProgressivaThis policy governs prior authorization and medical-necessity coverage for Pasatru (garetosmab-grts) in adults with fibrodysplasia ossificans progressiva, subject to coverage criteria, documentation requirements, and dosing limits.All Blue Cross Blue Shield - Iowa updates
- Prior AuthClinical/Medical PolicyEff. 2026-10-16Zenbexus (iberdomide) Coverage PolicyThis policy governs prior authorization and medical necessity coverage for Zenbexus (iberdomide) for multiple myeloma and specified compendial indications. Coverage requires applicable prior treatment, combination therapy, continuation, and dosing criteria.All Blue Cross Blue Shield - Iowa updates
- Prior AuthClinical/Medical PolicyEff. 2026-10-08Ingrezza (valbenazine)This policy governs prior authorization coverage for Ingrezza (valbenazine) for adults with tardive dyskinesia and chorea associated with Huntington's disease. Coverage requires applicable clinical criteria, supporting documentation, appropriate prescriber involvement, and compliance with quantity limits.All Blue Cross Blue Shield - Iowa updates
- Prior AuthClinical/Medical PolicyEff. 2026-10-03Afrezza (insulin human inhalation powder) Coverage CriteriaThis policy governs prior authorization and medical-necessity determinations for Afrezza for members with type 1 or type 2 diabetes mellitus, including clinical eligibility, required documentation, preferred-therapy prerequisites, approval duration, exclusions, and quantity limits.All Blue Cross Blue Shield - Iowa updates
- Prior AuthClinical/Medical PolicyEff. 2026-10-03Casgevy (exagamglogene autotemcel) Coverage CriteriaThis policy governs prior authorization and medical-necessity coverage for Casgevy in members with sickle cell disease or transfusion-dependent beta-thalassemia. Coverage requires indication-specific clinical, laboratory, treatment-history, specialist-prescriber, and safety criteria.All Blue Cross Blue Shield - Iowa updates
- Prior AuthClinical/Medical PolicyEff. 2026-10-03Tryngolza (olezarsen) CoverageThis policy governs prior authorization and continued coverage of Tryngolza (olezarsen) for adults with familial chylomicronemia syndrome or severe hypertriglyceridemia. Coverage requires applicable clinical criteria, documentation, dietary management, and quantity limits.All Blue Cross Blue Shield - Iowa updates
- Prior AuthClinical/Medical PolicyEff. 2026-10-03Vyjuvek (beremagene geperpavec-svdt) Coverage CriteriaPrior authorization coverage for Vyjuvek to treat wounds in adult and pediatric members with dystrophic epidermolysis bullosa and COL7A1 mutations, including clinical eligibility, documentation, dosing, continuation, and billing requirements.All Blue Cross Blue Shield - Iowa updates
- Prior AuthClinical/Medical PolicyEff. 2026-10-03Zoryve (roflumilast) topical therapy coverageThis policy governs prior authorization and medical-necessity coverage for Zoryve cream and foam used to treat plaque psoriasis, atopic dermatitis, and seborrheic dermatitis when applicable age, diagnosis, prior-treatment response or intolerance, quantity, and continuation requirements are met.All Blue Cross Blue Shield - Iowa updates
- Prior AuthClinical/Medical PolicyEff. 2026-10-03Zycubo (copper histidinate) CoverageThis policy governs prior authorization and medical-necessity coverage for Zycubo in pediatric and continuing-treatment patients with Menkes disease. Coverage depends on diagnosis, age or prior treatment status, clinical response, documentation, prescriber qualifications, and applicable quantity limits.All Blue Cross Blue Shield - Iowa updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-30Austedo and Austedo XR (deutetrabenazine) CoveragePrior authorization coverage for Austedo and Austedo XR in adults with chorea associated with Huntington's disease or tardive dyskinesia, subject to clinical criteria, documentation, specialist requirements, and dosing or quantity limits.All Blue Cross Blue Shield - Iowa updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-30Emrelis (telisotuzumab vedotin-tllv) Coverage for Non-Small Cell Lung CancerThis policy governs prior authorization and medical-necessity coverage for Emrelis in adult members with specified locally advanced, recurrent, or metastatic non-squamous non-small cell lung cancer. Coverage requires the documented clinical, biomarker, prior-treatment, and continuation criteria described in the policy.All Blue Cross Blue Shield - Iowa updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-30Icotyde (icotrokinra) Coverage for Plaque PsoriasisThis policy governs prior authorization and coverage of Icotyde for moderate-to-severe plaque psoriasis in adults and pediatric patients age 12 years and older. It establishes preferred-product requirements, clinical approval criteria, documentation requirements, continuation criteria, and quantity limits.All Blue Cross Blue Shield - Iowa updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-30Livmarli (maralixibat) Coverage CriteriaThis policy governs prior authorization and coverage of Livmarli (maralixibat) for cholestatic pruritus associated with Alagille syndrome or progressive familial intrahepatic cholestasis, subject to clinical, age, prescriber, exclusion, continuation, and dosing requirements.All Blue Cross Blue Shield - Iowa updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-27Familial Amyloid PolyneuropathyCoverage and prior authorization for Onpattro and Wainua in adults with polyneuropathy due to hereditary transthyretin-mediated amyloidosis, including preferred products, exception criteria, documentation, dosing limits, and continuation requirements.All Blue Cross Blue Shield - Iowa updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-23Skyrizi coverage and prior authorizationThis policy governs coverage and prior authorization requirements for risankizumab-rzaa (Skyrizi) for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It applies to members whose plans include the benefit, subject to contract exclusions, limitations, and applicable benefit terms.All Blue Cross Blue Shield - Iowa updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-21Cavhanza and Danziten (nilotinib) Coverage CriteriaPrior authorization and medical-necessity criteria for Cavhanza and Danziten (nilotinib) in adult members with Philadelphia chromosome-positive chronic myeloid leukemia.All Blue Cross Blue Shield - Iowa updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-21Jublia and TavaboroleThis policy governs prior authorization and medical-necessity coverage for Jublia (efinaconazole) and generic tavaborole topical treatment of toenail onychomycosis when clinical, laboratory, treatment-failure, and noncosmetic-use criteria are met.All Blue Cross Blue Shield - Iowa updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-21Lumvoa and Tepezza for thyroid eye diseaseThis policy governs prior authorization and medical-necessity coverage for Lumvoa (veligrotug-vvze) and Tepezza (teprotumumab-trbw) to treat thyroid eye disease. Coverage applies when product-specific clinical, specialist-prescriber, documentation, and treatment-history requirements are met, subject to the member's benefit contract.All Blue Cross Blue Shield - Iowa updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-17Spravato (esketamine) Nasal SprayThis policy governs prior authorization and medical necessity determinations for Spravato (esketamine) nasal spray for adults with treatment-resistant depression or major depressive disorder with acute suicidal ideation or behavior, subject to applicable clinical criteria, documentation, supervision, monitoring, and exclusions.All Blue Cross Blue Shield - Iowa updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-14Besremi (ropeginterferon alfa-2b-njft) Coverage and Prior AuthorizationThis policy governs coverage and prior authorization for Besremi (ropeginterferon alfa-2b-njft) for adults with polycythemia vera and specified compendial hematologic and lymphoid malignancies. It establishes initial and continuation approval criteria, authorization duration, and quantity limits.All Blue Cross Blue Shield - Iowa updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-14Hepcludex Coverage for Chronic Hepatitis Delta Virus InfectionThis policy governs prior authorization and coverage of Hepcludex (bulevirtide-gmod) for adults with chronic hepatitis delta virus infection when documented clinical, laboratory, prescriber, and liver-disease criteria are met.All Blue Cross Blue Shield - Iowa updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-14Inrebic (fedratinib) Coverage PolicyThis policy governs prior authorization coverage for Inrebic (fedratinib) in members being treated for specified myelofibrosis, myeloproliferative neoplasms, and myeloid/lymphoid neoplasms. Coverage requires an eligible diagnosis and satisfaction of applicable initial or continuation criteria, subject to plan benefits and exclusions.All Blue Cross Blue Shield - Iowa updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-14Ojjaara (momelotinib) Coverage CriteriaPrior authorization and medical-necessity coverage for Ojjaara (momelotinib) in adults with myelofibrosis, myelofibrosis-associated anemia, myeloproliferative neoplasms, or myeloid/lymphoid neoplasms with eosinophilia, subject to clinical criteria, documentation requirements, continuation requirements, and quantity limits.All Blue Cross Blue Shield - Iowa updates
Tool Description
Search Blue Cross Blue Shield - Iowaprior authorization policies by drug name, procedure, or policy title. Results include any policy that mentions prior authorization requirements (drug coverage criteria, imaging guidelines, site-of-service rules) not just documents titled “prior authorization.” Every result links to a full policy page with clinical criteria, covered billing codes, documentation requirements, and effective dates.
Filter by payer, specialty, policy type, or effective year; or search directly for a drug (“Wegovy,” “Ozempic”), a procedure (“MRI,” “knee arthroplasty”), or a policy number.
Coverage spans 110+ payers. Jump straight to the busiest prior-auth publishers: UnitedHealthcare, Cigna, Aetna, Anthem, and Centene. You can also browse the full policy updates feed.
Pair a prior-auth search with the billing code lookup to confirm the CPT or J-code on the claim, the payer lookup for plan footprint, and payer profiles for contacts and coverage context.
FAQ
Prior Authorization by Payer
Go deeper
Explore OpenPayer Data
Prior auth requirements change all the time. Keep up with every payer policy update in the live policy feed, or browse payers with prior authorization policies.
Toolbox
More OpenPayer Tools
- Billing Code LookupSearch CPT, HCPCS, J-codes, DRG, and dental codes by number or procedure name.
- Billing Code Reimbursement RatesBuild a reimbursement rate report across any mix of billing codes and states, comparing commercial payers against Medicare.
- Payer Comparison DashboardPick 2-5 payers to compare market share, premium, and membership by region, all at once.
- Facility Comparison DashboardPick 2-6 hospital facility types (or add a specific hospital) to compare facility count, revenue, net income, and Medicare/Medicaid payer mix by region, all at once.
- Healthcare Provider & Facility LookupFind hospitals and healthcare facilities by name, taxonomy, facility type, ownership, or state.
- Health Insurance Payer LookupSearch national health insurance payers and health plans by name and state presence.
- Provider Taxonomy Code LookupSearch NUCC taxonomy codes by code, specialty, grouping, or classification.
- CPT Modifier LookupSearch CPT modifiers by code or name — descriptions, when to use them, and payer policy context.
- Timely Filing LookupFind payer timely filing policies: claim deadlines, corrected claim windows, and appeal timeframes.
- Coverage Criteria LookupSearch payer coverage criteria and medical necessity requirements by drug, procedure, or payer.
- Payer Contact DirectoryClaims, prior authorization, provider services, and appeals contacts for health insurance payers.
Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.